Although PD-L1, TMB, tumor-infiltrating lymphocytes, neoantigen burden, and TIS scores are reported to have potential in predicting immunotherapy efficiency 56, these biomarkers face significant challenges. This evidence concerns the gene CD274 and neoplasm.